NTN1 and pancreatic neoplasm: A phase I clinical trial is ongoing to test the NTN1-blocking antibody NP137 in combination with FOLFIRINOX in patients with locally advanced pancreatic cancer (ClinicalTrials.gov identifier: NCT05546853).